Evidence map›Paper›PMID 24685267›Full record

ArticleBiomaterials2014

Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy.

Liang Leng, Yuebing Wang, Ningning He, Di Wang, Qianjie Zhao, Guowei Feng, Weijun Su, Yang Xu, Zhongchao Han, Deling Kong and 3 more

Open access · greenAbstract read
In one paragraph

Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 85 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. NoninvasiveWorld journal of stem cells · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Liang LengNankai University School of Medicine, Tianjin, China; The Key Laboratory of Bioactive Materials, Ministry of Education, Nankai University, College of Life Science, Tianjin, China.
Yuebing WangNankai University School of Medicine, Tianjin, China.
Ningning HeNankai University School of Medicine, Tianjin, China.
Di WangNankai University School of Medicine, Tianjin, China.
Qianjie ZhaoNankai University School of Medicine, Tianjin, China.
Guowei FengNankai University School of Medicine, Tianjin, China.
Weijun SuNankai University School of Medicine, Tianjin, China.
Yang XuNankai University School of Medicine, Tianjin, China.
Zhongchao HanState Key Lab of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
Deling KongThe Key Laboratory of Bioactive Materials, Ministry of Education, Nankai University, College of Life Science, Tianjin, China.
Zhen ChengDepartment of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Rong XiangNankai University School of Medicine, Tianjin, China.
Zongjin LiNankai University School of Medicine, Tianjin, China; The Key Laboratory of Bioactive Materials, Ministry of Education, Nankai University, College of Life Science, Tianjin, China. Electronic address: zongjinli@nankai.edu.cn.
Nankai University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNStanford University · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

The tumor tropism of mesenchymal stem cells (MSCs) makes them an excellent delivery vehicle used in anticancer therapy. However, the exact mechanisms of MSCs involved in tumor microenvironment are still not well defined. Molecular imaging technologies with the versatility in monitoring the therapeutic effects, as well as basic molecular and cellular processes in real time, offer tangible options to better guide MSCs mediated cancer therapy. In this study, an in situ breast cancer model was developed with MDA-MB-231 cells carrying a reporter system encoding a double fusion (DF) reporter gene consisting of firefly luciferase (Fluc) and enhanced green fluorescent protein (eGFP). In mice breast cancer model, we injected human umbilical cord-derived MSCs (hUC-MSCs) armed with a triple fusion (TF) gene containing the herpes simplex virus truncated thymidine kinase (HSV-ttk), renilla luciferase (Rluc) and red fluorescent protein (RFP) into tumor on day 13, 18, 23 after MDA-MB-231 cells injection. Bioluminescence imaging of Fluc and Rluc provided the real time monitor of tumor cells and hUC-MSCs simultaneously. We found that tumors were significantly inhibited by hUC-MSCs administration, and this effect was enhanced by ganciclovir (GCV) application. To further demonstrate the effect of hUC-MSCs on tumor cells in vivo, we employed the near infrared (NIR) imaging and the results showed that hUC-MSCs could inhibit tumor angiogenesis and increased apoptosis to a certain degree. In conclusion, hUC-MSCs can inhibit breast cancer progression by inducing tumor cell death and suppressing angiogenesis. Moreover, molecular imaging is an invaluable tool in tracking cell delivery and tumor response to hUC-MSCs therapies as well as cellular and molecular processes in tumor.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleHumansIn Situ Nick-End LabelingMesenchymal Stem CellsMiceMice, NudeMolecular ImagingBioluminescence imaging (BLI)Cancer therapyMesenchymal stem cells (MSCs)Molecular imagingNear infrared (NIF) imaging

Identifiers

PMID24685267
PMCPMC4414495
OpenAlexW1979811980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.